Press Releases
Page 2 of 24
LesEchos/Investir–Presentation of Judith Greciet at Direct Dirigeants event
(in French only)
Tags: Financials & Corporate
11/06/2019
Onxeo to attend the European Healthcare Conference organized by Bryan, Garnier & Co.
Paris (France), November 5, 2019 – 5:45 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]
Tags: Financials & Corporate
11/05/2019
Onxeo Receives U.S. Patent and Trademark Office Notice of Allowance for New Patent Protecting Combination of AsiDNA™ with Any PARP Inhibitor for Cancer Treatment
Combination patent to be granted in the U.S. until 2036 Paris (France), November 4, 2019 – 5:45 pm CEST – […]
Tags: AsiDNA™
11/04/2019
Onxeo, Winner of the Innov’up Leader PIA Call for Projects, Receives Funding of €495,000
The winning project aims to develop a drug candidate in immuno-oncology from the platON™ platform Funding from the French State […]
Tags: Financials & Corporate
10/17/2019
Onxeo to Present Final Results of DRIIV-1 Phase 1 Study of AsiDNA™ in Advanced Solid Tumors at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Positive Safety and Activity Results from DRIIV-1 Led to Initiation of Ongoing DRIIV-1b Phase 1b Study of AsiDNA™ in Combination […]
Tags: AsiDNA™
10/15/2019
Onxeo receives EPO Intent-to-Grant Notice for New Patent strengthening European Protection of Compounds sourced from its platON™ Platform
This new patent protects in particular AsiDNA™ and its related compounds for their use in the treatment of cancer, alone […]
Tags: AsiDNA™
10/14/2019
Onxeo announces positive intermediate results from the first part of the DRIIV-1b study evaluating AsiDNA™ in combination with chemotherapy
Stabilized disease without tumor progression for two of the three treated patients who are still receiving treatment with AsiDNA™ […]
Tags: AsiDNA™
09/18/2019
Onxeo to Attend Key Investor and Scientific Conferences
Paris (France), September 11, 2019 – 5.45 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), (“Onxeo” or “the Company”), […]
Tags: Financials & Corporate
09/11/2019
Onxeo Reports Half-Year 2019 Financial Results and Provides Business Update
Finalization of DRIIV-1 Phase 1 study confirming AsiDNA™ activity and safety profile Initiation of DRIIV-1b study of AsiDNA™ with chemotherapy, […]
Tags: Financials & Corporate
07/25/2019
The equity research company KEPLER CHEUVREUX initiates the coverage of ONXEO with a “Buy” recommendation
Paris (France), July 1st, 2019 – 7:00 a.m. CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (hereinafter “Onxeo” or […]
Tags: Financials & Corporate
07/01/2019
Page 2 of 24
Last updated on